In the Archives

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC
FreeIn the Archives

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC

On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.